Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.
The company is advancing Vispa-cel, which targets CD19 for lymphoma, and CB-011, which targets BCMA for multiple myeloma. Both programs received significant clinical updates late last year, and early results support best-in-class potential, Haurwitz said during the session moderated by analyst Alec Stranahan.
